ADDING MULTIMEDIA Candela Receives Registration Approval to Market the Alex TriVantage Laser in Brazil
July 29 2009 - 1:57PM
Business Wire
Candela Corporation (NASDAQ:CLZR) today announced that it has
received registration approval from the Brazilian National Health
Surveillance Agency (ANVISA) to market the Candela Alex TriVantage®
multi-wavelength, q-switched laser system in Brazil.
“Until now, providing high quality and effective treatment for
pigmented lesions and multi-color tattoos meant that Brazilian
doctors needed to own at least two different lasers. With Alex
TriVantage’s Laser-Pumped-Laser (LPL) technology, a greater number
of doctors will be able to offer a wider variety of services
assured of the ability to provide treatment regardless of the
patient’s skin color,” said Candela President and Chief Executive
Officer, Gerard E. Puorro. “This approval increases the number of
Candela products marketed in Brazil, enabling us to offer a more
complete range of highly effective aesthetic laser solutions.”
Unique, q-switched Laser-Pumped-Laser (LPL) technology provides
755 nm, 532 nm and 1064 nm output wavelengths, making Alex
TriVantage extremely versatile. The addition of a long-pulse mode
at 755nm offers advanced treatments for a wider variety of
pigmented lesions without side effects. Beyond the treatment of
benign pigmented lesions and the removal of multi-color tattoo
inks, Alex TriVantage enhances the results of many skin
rejuvenation treatments, making it an ideal system for optimizing
fractional and other rejuvenation treatment results.
The Alex TriVantage platform has received wide acclaim including
a recent feature on ABC’s nationally broadcasted “The View”. To see
dermatologist Suzanne Kilmer, MD from Sacramento, CA performing a
tattoo removal treatment, visit Candela’s website at
www.candelalaser.com/theview.
For more information, contact jane.smith@candelalaser.com or
visit www.alextrivantage.com. To speak to our representative in
Brazil, contact Edson Veiga at edson@medson.com.br or
55-21-2431-5577.
About
CANDELA: Candela Corporation manufactures and
distributes innovative clinical solutions that enable physicians,
surgeons, and personal care practitioners to treat selected
cosmetic and medical conditions using lasers, aesthetic laser
systems, and other advanced technologies. Founded near Boston in
1970, Candela markets and services its products in 86 countries
from offices and distributors in the United States, Europe, Japan,
China and other Asian locations. Candela established the aesthetic
laser market 20 years ago, and currently has an installed base of
over 13,500 systems worldwide. Visit Candela on the Web at
http://www.candelalaser.com.
Safe Harbor
Statement: Except for the historical information
contained herein, this news release contains forward-looking
statements that constitute Candela Corporation’s current
intentions, hopes, beliefs, expectations or predictions of the
future, which are therefore inherently subject to risks and
uncertainties. These statements include declarations regarding our
or our management’s beliefs and current expectations. In some
cases, you can identify forward-looking statements by terminology
such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,”
“believes,” “estimates,” “predicts,” “potential” or “continue” or
the negative of such terms or other comparable terminology. These
forward-looking statements are subject to inherent risks and
uncertainties in predicting future results and conditions that
could cause the actual results to differ materially from those
projected in these forward-looking statements. The risks and
uncertainties that may affect forward-looking statements include,
among others: the availability of, and our ability to successfully
implement strategic and operational alternatives, the pendency of
re-examinations of the ‘844 Patent and the ‘568 Patent before the
PTO, our alleged infringement of the ‘844 Patent and the ‘568
Patent, the validity of the ‘844 Patent and the ‘568 Patent, our
expected legal expenses, our exploration of strategic and
operational alternatives, the expected recovery of our industry,
our future revenue, gross margin, expense levels and earnings, our
growth prospects, market acceptance of our products, the strength
of our distribution channels, our ability to add new products, our
ability to expand regulatory approvals and the liquidity of our
common stock, the cancellation or deferral of customer orders, the
risk of a material adverse judgment or increased litigation-related
expenses in pending litigation matters, dependence on a small
number of strategic distribution relationships, difficulties in the
timely development and market acceptance of new products,
unanticipated increases in expenses, market developments that vary
from the current public expectations concerning the growth of the
laser industry, increased competitive pressures, changes in
economic conditions, or difficulties in obtaining timely regulatory
approvals. Further information on factors that could affect
Candela's performance is included in Candela's periodic reports
filed with the SEC. Candela cautions readers not to place undue
reliance upon any such forward-looking statements, which speak only
as of the date made. Candela expressly disclaims any obligations or
undertaking to release publicly any updates or revisions to any
such statements to reflect any change in Candela's expectations or
any change in events, conditions or circumstances on which any such
statement is based.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6018178&lang=en
Candela (MM) (NASDAQ:CLZR)
Historical Stock Chart
From Oct 2024 to Nov 2024
Candela (MM) (NASDAQ:CLZR)
Historical Stock Chart
From Nov 2023 to Nov 2024